SPY326.52+2.56 0.79%
DIA264.35+1.07 0.41%
IXIC10,745.28+157.46 1.49%
News
KROS
--
0.00%
--
The Daily Biotech Pulse: Chiasma, Heron Await FDA Decisions, DBV Restructures, 3 Biopharmas Make Wall Street Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 25)
Benzinga · 06/26 12:28
Keros Therapeutics To Join Russell 2000 Index
LEXINGTON, Mass, June 26, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on the discovery,
Benzinga · 06/26 11:03
Keros Therapeutics Set to Join Russell 2000® Index
Keros Therapeutics, Inc. (“Keros” or the “Company”) (KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with
GlobeNewswire · 06/26 11:01
Keros Therapeutics (KROS) in Focus: Stock Moves 6.8% Higher
Keros Therapeutics (KROS) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Zacks · 06/24 12:34
The Daily Biotech Pulse: GlaxoSmithKline, IDEAYA Strike Oncology Partnership, Decision Day For Merck, Adverum's New CEO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 16)
Benzinga · 06/16 12:15
Keros Therapeutics Highlihts Presentation Of Results From Clinical And Preclinical Studies Investigating KER-050, Along With Preclinical Data From Its ALK2 Inhibitor Program, At European Hematology Association 2020 Annual Meeting
  Poster presentation highlights Phase 1 clinical trial data demonstrating tolerability, pharmacokinetics and pharmacodynamics of KER-050 in healthy postmenopausal women. Poster presentations introduce data
Benzinga · 06/12 11:02
Keros Therapeutics Presents Results from Clinical and Preclinical Studies Investigating KER-050, along with Preclinical Data from its ALK2 Inhibitor Program, at the European Hematology Association 2020 Annual Meeting
Poster presentations introduce data demonstrating KER-050 robustly promoted hematopoiesis in multiple animal species in preclinical studies and support a potentially novel mechanism of action. Oral presentation on a novel ALK2 kinase inhibitor that suppressed
GlobeNewswire · 06/12 11:01
The Daily Biotech Pulse: Positive Readout For Kezar, AstraZeneca Stitches Oncology Partnership, D-Day For Merck's Triple Combo Antibiotic
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peak (Biotech Stocks Hitting 52-week Highs June 3)
Benzinga · 06/04 12:13
Keros Therapeutics To Present At The Jefferies 2020 Virtual Healthcare Conference
GlobeNewswire · 05/28 12:01
Piper Sandler Maintains Overweight on Keros Therapeutics, Raises Price Target to $45
Piper Sandler maintains Keros Therapeutics (NASDAQ:KROS) with a Overweight and raises the price target from $35 to $45.
Benzinga · 05/27 12:18
Kinnate Biopharma Appoints Nima Farzan As Chief Executive Officer
Benzinga · 05/27 12:15
Keros Therapeutics Reports Recent Business Highlights and First Quarter 2020 Financial Results
LEXINGTON, Mass., May 22, 2020 -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and.
GlobeNewswire · 05/22 11:00
Keros Therapeutics to Present at the Virtual 25th Annual Congress of the European Hematology Association
Keros Therapeutics, Inc. (“Keros”) (KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medica
GlobeNewswire · 05/14 13:15
The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 12)
Benzinga · 05/13 11:40
3 Strong Buy Biotech Stocks With Plenty of Upside Ahead
TipRanks · 05/05 16:46
3 Keros Analysts On Why Biopharma Is A Compelling Investment Opportunity
Keros Therapeutics Inc (NASDAQ: KROS), a clinical-stage biopharma focused on the development of treatments for rare hematologic and musculoskeletal disorders,
Benzinga · 05/04 18:41
HC Wainwright & Co. Initiates Coverage On Keros Therapeutics with Buy Rating, Announces Price Target to $50
HC Wainwright & Co. analyst Andrew Fein initiates coverage on Keros Therapeutics (NASDAQ:KROS) with a Buy rating and announces Price Target to $50.
Benzinga · 05/04 15:55
UPDATE: Jefferies On Keros Therapeutics Notes 'More importantly, potential advantages from early data, if proven in Ph2 (preliminary data potentially by YE21 by our est.), could lead to >$1B opportunity, offering meaningful upside to current valuation'
Benzinga · 05/04 15:33
UPDATE: Jefferies Initiates Keros Therapeutics With Buy, $37 Target Notes 'We view clinical risks for lead product/KER-050 as somewhat mitigated from recently approved XLRN's Reblozyl'
Benzinga · 05/04 15:33
UPDATE: Piper Sandler Initiates Keros Therapeutics With Overweight, $35 Target Thinks Co. 'is a compelling investment opportunity given the power (and external validation) of their lead asset and therapeutic platform to drive future value creation'
Benzinga · 05/04 15:24